Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp > New post

<< Previous

Bullboard Posts

Next >>

Comment by throwmeaboneon Feb 11, 2021 7:41pm

189 Views

Post# 32548151

RE:New post

Thot u said u we're gonna contribute forthwith! It took you 54 minutes to figure out how to post, and that's the best u could come up with? No slick analysis? No pumping the COVID trial? Nuthin?!! I take it back, you're not an orateur! You're a pumper sent to drive the price up!

oldnwise!? Old yes, it took u 54 minutes to post, nuthin? Wise? Again, 54 min! For drivel...old crusty maybe! do u get paid by the post?

just sayin...

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth